



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **YAMADA, Yoshiji, et al.**

Group Art Unit: **3762**

Serial No.: **10/517,605**

Examiner: **Not Yet Assigned**

Filed: **December 21, 2004**

P.T.O. Confirmation No.: **1240**

For: **METHOD OF DIAGNOSING RISK OF MYOCARDIAL INFARCTION**

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

November 1, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.


No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS,  
HANSON & BROOKS, LLP

  
James E. Armstrong, IV  
Attorney for Applicants  
Reg. No. 42,266



23850

PATENT TRADEMARK OFFICE

JAM/rk  
Atty. Docket No. 040677  
Suite 1000  
1725 K Street, N.W.  
Washington, D.C. 20006  
(202) 659-2930

Enclosures: PTO-1449 and references (6)

**INFORMATION  
DISCLOSURE  
CITATION**

14 PCT NO-1449

Atty. Docket No. 040677 Serial No. 10/517,605

Applicant(s): YAMADA, Yoshiji, et al.

Filing Date: December 21, 2004 Group Art Unit: 3762

O P E R A T I O N S  
NOV 01 2005  
P A T E N T E X A M I N E R  
Initial

**U.S. PATENT DOCUMENTS**

Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	AA AB				

**FOREIGN PATENT DOCUMENTS**

Document No.	Date	Country	Translation (Yes or No)
_____	AC AD		

**OTHER DOCUMENTS**

/KH/	AE	A copy of the European Patent Office Communication (including Supplementary Partial European Search Report) for corresponding European patent application No. 03712817(PCT/JP0303477), dated October 13, 2005.
/KH/	AF	Hung-I. Yeh, et al. "Connexin37 gene polymorphism and coronary artery disease in Taiwan," <i>International Journal of Cardiology</i> ; Vol. 81, pp.251-255 (2001).
/KH/	AG	Werner Koch, et al. "Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction;" <i>Atherosclerosis</i> ; Vol. 159, pp.137-144 (2001).
/KH/	AH	M. Boerma, et al. "A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development;" <i>Journal of Internal Medicine</i> ; Vol. 246, pp.211-218 (1999).
/KH/	AI	Elvis Brscic, et al. "Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up;" <i>American Heart Journal</i> ; Vol. 139, No.6, pp.979-984 (2000).
/KH/	AJ	Juliano C. Padovani, et al. "Gene Polymorphisms in the TNF Locus and the Risk of Myocardial Infarction;" <i>Thrombosis Research</i> ; Vol.100, pp.263-269 (2000).

Examiner

/Kenneth Horlick/

Date Considered

05/28/2008